Ligand Pharmaceuticals (LGND) EPS (Weighted Average and Diluted) Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) EPS (Weighted Average and Diluted) Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
251.11% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-13.31% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
102.51% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-79.34% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-103.05% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
61.45% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Ligand Pharmaceuticals |
5.47 Bn |
4.69 Bn |
48.45 Mn |
69.68% |
| Date | Value |
|---|
| Mar 31, 2026 |
69.68% |
| Dec 31, 2025 |
229.76% |
| Sep 30, 2025 |
1,556.41% |
| Jun 30, 2025 |
108.33% |
| Mar 31, 2025 |
-146.53% |
| Dec 31, 2024 |
-263.11% |
| Sep 30, 2024 |
33.90% |
| Jun 30, 2024 |
-2,315.38% |
| Mar 31, 2024 |
95.47% |
| Dec 31, 2023 |
219.77% |
| Sep 30, 2023 |
-205.36% |
| Jun 30, 2023 |
-82.43% |
| Mar 31, 2023 |
415.58% |
| Dec 31, 2022 |
-352.63% |
| Sep 30, 2022 |
-52.94% |
| Jun 30, 2022 |
-65.09% |
| Mar 31, 2022 |
-158.33% |
| Dec 31, 2021 |
-154.29% |
| Sep 30, 2021 |
383.33% |
| Jun 30, 2021 |
60.61% |
